Clinical trialNCT04521413Active, not recruitingPhase 1/PHASE2Interventional

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

SponsorTreadwell Therapeutics, IncEnrollment170Advanced Solid Malignancies

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Omid Hamid, Dr
The Angeles Clinic, Los Angeles
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Cross Cancer Institute
Edmonton, Alberta, Canada
the Ottawa Hospital
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada

Hong Kong

Prince of Wales Hospital
Shatin, Hong Kong

United States

University of California San Diego
La Jolla, California, United States
the Angeles Clinic
Los Angeles, California, United States
Yale Cancer Center
New Haven, Connecticut, United States
Florida Cancer Specialists
Sarasota, Florida, United States
Start - Mid-West
Grand Rapids, Michigan, United States
Scri - Nashville
Nashville, Tennessee, United States
Md Anderson
Houston, Texas, United States
Start - San Antonio
San Antonio, Texas, United States
Virginia Cancer Specialist
Fairfax, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CFI-402411Pembrolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2020
Primary completion: 30 Nov 2025
Completion: 31 Dec 2025
Last update posted: 21 May 2025
Registered enrollment: 170
Registry id: NCT04521413

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.